201 related articles for article (PubMed ID: 28039467)
1. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
Bonuccelli G; Peiris-Pages M; Ozsvari B; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Oncotarget; 2017 Feb; 8(6):9868-9884. PubMed ID: 28039467
[TBL] [Abstract][Full Text] [Related]
2. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.
Sumi NJ; Kuenzi BM; Knezevic CE; Remsing Rix LL; Rix U
ACS Chem Biol; 2015 Dec; 10(12):2680-6. PubMed ID: 26390342
[TBL] [Abstract][Full Text] [Related]
3. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
[No Abstract] [Full Text] [Related]
4. Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.
Miettinen TP; Peltier J; Härtlova A; Gierliński M; Jansen VM; Trost M; Björklund M
EMBO J; 2018 May; 37(10):. PubMed ID: 29669860
[TBL] [Abstract][Full Text] [Related]
5. Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.
Jiang B; Wang ES; Donovan KA; Liang Y; Fischer ES; Zhang T; Gray NS
Angew Chem Int Ed Engl; 2019 May; 58(19):6321-6326. PubMed ID: 30802347
[TBL] [Abstract][Full Text] [Related]
6. A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.
Menon M; Elliott R; Bowers L; Balan N; Rafiq R; Costa-Cabral S; Munkonge F; Trinidade I; Porter R; Campbell AD; Johnson ER; Esdar C; Buchstaller HP; Leuthner B; Rohdich F; Schneider R; Sansom O; Wienke D; Ashworth A; Lord CJ
Sci Rep; 2019 Jan; 9(1):201. PubMed ID: 30655555
[TBL] [Abstract][Full Text] [Related]
7. Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronized cell cycle progression in human cell culture.
Trotter EW; Hagan IM
Open Biol; 2020 Oct; 10(10):200200. PubMed ID: 33052073
[TBL] [Abstract][Full Text] [Related]
8. A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas.
Hadjadj D; Kim SJ; Denecker T; Ben Driss L; Cadoret JC; Maric C; Baldacci G; Fauchereau F
Aging (Albany NY); 2017 Dec; 9(12):2695-2716. PubMed ID: 29283884
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
Li X; Seebacher NA; Garbutt C; Ma H; Gao P; Xiao T; Hornicek FJ; Duan Z
Cell Death Dis; 2018 May; 9(5):446. PubMed ID: 29670090
[TBL] [Abstract][Full Text] [Related]
10. The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer.
Liu C; Huang Y; Cui Y; Zhou J; Qin X; Zhang L; Li X; Li Y; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Hu D; Xiao R; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Qin T; You L; Lu F; Sun C
Front Immunol; 2021; 12():799171. PubMed ID: 35095879
[TBL] [Abstract][Full Text] [Related]
11. Comparative Analysis of Primary Ovarian Cancer Cells and Established Cell Lines as a New Tool for Studies on Ovarian Cancer Cell Complexity.
Szyposzynska A; Bielawska-Pohl A; Paprocka M; Bar J; Murawski M; Klimczak A
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791431
[TBL] [Abstract][Full Text] [Related]
12. CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis.
Birnhuber A; Egemnazarov B; Biasin V; Bonyadi Rad E; Wygrecka M; Olschewski H; Kwapiszewska G; Marsh LM
Respir Res; 2020 Jul; 21(1):167. PubMed ID: 32616042
[TBL] [Abstract][Full Text] [Related]
13. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.
Uzhachenko RV; Bharti V; Ouyang Z; Blevins A; Mont S; Saleh N; Lawrence HA; Shen C; Chen SC; Ayers GD; DeNardo DG; Arteaga C; Richmond A; Vilgelm AE
Cell Rep; 2021 Apr; 35(1):108944. PubMed ID: 33826903
[TBL] [Abstract][Full Text] [Related]
14. MitoTracker Deep Red (MTDR) Is a Metabolic Inhibitor for Targeting Mitochondria and Eradicating Cancer Stem Cells (CSCs), With Anti-Tumor and Anti-Metastatic Activity
Sargiacomo C; Stonehouse S; Moftakhar Z; Sotgia F; Lisanti MP
Front Oncol; 2021; 11():678343. PubMed ID: 34395247
[TBL] [Abstract][Full Text] [Related]
15. Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity.
Yu L; Liu S; Zhang C; Zhang B; Simões BM; Eyre R; Liang Y; Yan H; Wu Z; Guo W; Clarke RB
Oncotarget; 2013 Dec; 4(12):2326-38. PubMed ID: 24334332
[TBL] [Abstract][Full Text] [Related]
16. [Role of PD 0332991 on the Proliferation and Apoptosis of Vascular Endothelial Cells].
Zhao C; Liu M; Li Y; Zhang H; Li Y; Gong H; Yuan Y; Li W; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):375-382. PubMed ID: 29764587
[TBL] [Abstract][Full Text] [Related]
17. Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition.
Beykou M; Arias-Garcia M; Roumeliotis TI; Choudhary JS; Moser N; Georgiou P; Bakal C
Sci Data; 2022 Jul; 9(1):395. PubMed ID: 35817775
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion.
Velez BC; Petrella CP; DiSalvo KH; Cheng K; Kravtsov R; Krasniqi D; Krucher NA
Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36562384
[TBL] [Abstract][Full Text] [Related]
19. The mitochondrial deoxyguanosine kinase is required for cancer cell stemness in lung adenocarcinoma.
Lin S; Huang C; Sun J; Bollt O; Wang X; Martine E; Kang J; Taylor MD; Fang B; Singh PK; Koomen J; Hao J; Yang S
EMBO Mol Med; 2019 Dec; 11(12):e10849. PubMed ID: 31633874
[TBL] [Abstract][Full Text] [Related]
20. A high-throughput screen identifies inhibitors of lung cancer stem cells.
She X; Gao Y; Zhao Y; Yin Y; Dong Z
Biomed Pharmacother; 2021 Aug; 140():111748. PubMed ID: 34044271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
